MRI-Based End-To-End Pediatric Low-Grade Glioma Segmentation and Classification

Can Assoc Radiol J. 2024 Feb;75(1):153-160. doi: 10.1177/08465371231184780. Epub 2023 Jul 4.

Abstract

Purpose: MRI-based radiomics models can predict genetic markers in pediatric low-grade glioma (pLGG). These models usually require tumour segmentation, which is tedious and time consuming if done manually. We propose a deep learning (DL) model to automate tumour segmentation and build an end-to-end radiomics-based pipeline for pLGG classification. Methods: The proposed architecture is a 2-step U-Net based DL network. The first U-Net is trained on downsampled images to locate the tumour. The second U-Net is trained using image patches centred around the located tumour to produce more refined segmentations. The segmented tumour is then fed into a radiomics-based model to predict the genetic marker of the tumour. Results: Our segmentation model achieved a correlation value of over 80% for all volume-related radiomic features and an average Dice score of .795 in test cases. Feeding the auto-segmentation results into a radiomics model resulted in a mean area under the ROC curve (AUC) of .843, with 95% confidence interval (CI) [.78-.906] and .730, with 95% CI [.671-.789] on the test set for 2-class (BRAF V600E mutation BRAF fusion) and 3-class (BRAF V600E mutation BRAF fusion and Other) classification, respectively. This result was comparable to the AUC of .874, 95% CI [.829-.919] and .758, 95% CI [.724-.792] for the radiomics model trained and tested on the manual segmentations in 2-class and 3-class classification scenarios, respectively. Conclusion: The proposed end-to-end pipeline for pLGG segmentation and classification produced results comparable to manual segmentation when it was used for a radiomics-based genetic marker prediction model.

Keywords: U-Net; convolutional neural network; molecular markers classification; pLGG; tumour segmentation.

MeSH terms

  • Area Under Curve
  • Child
  • Genetic Markers
  • Glioma* / pathology
  • Humans
  • Magnetic Resonance Imaging / methods
  • Proto-Oncogene Proteins B-raf*

Substances

  • Genetic Markers
  • Proto-Oncogene Proteins B-raf